title: Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome.
abstract: OBJECTIVE
  To determine the possible role of anti-Müllerian hormone (AMH) in the diagnosis of polycystic ovary syndrome (PCOS) with a larger population of women and to evaluate its role as a new diagnostic marker.
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  A total of 570 women, with PCOS (n = 419) and without PCOS (n = 151).
  
  
  METHODS
  Serum basal hormone; AMH, follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin, and thyroid-stimulating hormone (TSH) levels were measured. Mean hormone levels were compared and the predictive value of serum AMH level was evaluated with the use of the receiver operating characteristic (ROC) curve analysis.
  
  
  RESULTS
  No statistically significant differences were found between PCOS women and control groups in terms of age, body mass index and TSH levels. Differences between mean serum, FSH, LH and estradiol levels and LH/FSH ratio were found to be statistically significant (p < 0.001). Mean serum AMH level was higher in PCOS women than in controls (7.34 vs. 2.24 ng/mL, p < 0.001). The area under the ROC curve assay yielded a satisfactory result of 0.916 (95% confidence interval 0.897-0.935, p < 0.0001). The best compromise between 89.8% specificity and 80% sensitivity was obtained with a cut-off value of 3.94 ng/mL for PCOS diagnosis.
  
  
  CONCLUSIONS
  Serum AMH measurement is very valuable in the diagnosis of PCOS women. The serum AMH level in women with hyperandrogenism or oligo-anovulation could indicate the diagnosis of PCOS when reliable ultrasonography data are not available or when typical clinical and laboratory findings are not available. The serum AMH level is a new and useful diagnostic tool in PCOS diagnosis.
authors: Department of Obstetrics & Gynecology, Division of Reproductive Endocrinology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
authors: Sezai
authors: S
authors: Sahmay
authors: Nil
authors: N
authors: Atakul
authors: Begüm
authors: B
authors: Aydogan
authors: Yavuz
authors: Y
authors: Aydin
authors: Metehan
authors: M
authors: Imamoglu
authors: Hakan
authors: H
authors: Seyisoglu
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D017588:Hyperandrogenism / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000175:diagnosis* / Q000000981:diagnostic imaging; D011237:Predictive Value of Tests; D011388:Prolactin / Q000097:blood; D012372:ROC Curve; D012680:Sensitivity and Specificity; D013972:Thyrotropin / Q000097:blood; D014463:Ultrasonography
chemical_list: D015415:Biomarkers; D004958:Estradiol; D054304:Anti-Mullerian Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin
keywords: anti-Müllerian hormone; diagnosis of polycystic ovary syndrome; elevated anti-Müllerian hormone; hyperandrogenism